Pacific Biosciences of California, Inc.
PACB · NASDAQ Global Select · USD
2,36USD
+0,105 (+4,66 %)Stand 9. Nov., 21:00
Kennzahlen
- Eröffnung
- 2,23
- Vortag
- 2,255
- Tagesspanne
- 2,16 – 2,43
- 52 Wochen
- 1,07 – 3,44
- Volumen
- 11,84 Mio.
- Ø Volumen
- 10,64 Mio.
- Börsenwert
- 733,56 Mio. $
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 2,2
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
- CEO
- Mark Van Oene
- Mitarbeitende
- 485
- Hauptsitz
- Menlo Park, CA, US
- Sektor
- Healthcare
- Branche
- Medical - Devices
- Börsengang
- 27. Okt. 2010
- Website
- pacb.com
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.